135 research outputs found
Novel pharmacodynamic biomarkers for MYCN protein and PI3K/AKT/mTOR pathway signaling in children with neuroblastoma
There is an urgent need for improved therapies for children with high-risk neuroblastoma
where survival rates remain low. MYCN amplification is the most common genomic change
associated with aggressive neuroblastoma and drugs targeting PI3K/AKT/mTOR, to activate
MYCNoncoprotein degradation, are entering clinical evaluation. Our aim was to develop and
validate pharmacodynamic (PD) biomarkers to evaluate both proof of mechanism and proof
of concept for drugs that block PI3K/AKT/mTOR pathway activity in children with neuroblastoma.
Wehave addressed the issue of limited access to tumor biopsies for quantitative detection
of protein biomarkers by optimizing a three-color fluorescence activated cell sorting
(FACS) method to purify CD45?/GD2+/CD56+ neuroblastoma cells from bone marrow. We
then developed a novel quantitative measurement of MYCN protein in these isolated neuroblastoma
cells, providing the potential to demonstrate proof of concept for drugs that inhibit
PI3K/AKT/mTOR signaling in this disease. In addition we have established quantitative
detection of three biomarkers for AKT pathway activity (phosphorylated and total AKT,
GSK3b and P70S6K) in surrogate platelet-rich plasma (PRP) frompediatric patients. Together
ournewapproachto neuroblastomacell isolation for protein detection and suite ofPD assays
provides for the first time the opportunity for robust, quantitative measurement of proteinbased
PD biomarkers in this pediatric patient population. These will be ideal tools to support
clinical evaluation of PI3K/AKT/mTOR pathway drugs and their ability to target MYCN oncoprotein
in upcoming clinical trials in neuroblastoma
Grand Challenges: Improving HIV Treatment Outcomes by Integrating Interventions for Co-Morbid Mental Illness.
In the fourth article of a five-part series providing a global perspective on integrating mental health, Sylvia Kaaya and colleagues discuss the importance of integrating mental health interventions into HIV prevention and treatment platforms. Please see later in the article for the Editors' Summary
Interrogating two schedules of the AKT inhibitor MK-2206 in patients with advanced solid tumors incorporating novel pharmacodynamic and functional imaging biomarkers.
PURPOSE: Multiple cancers harbor genetic aberrations that impact AKT signaling. MK-2206 is a potent pan-AKT inhibitor with a maximum tolerated dose (MTD) previously established at 60 mg on alternate days (QOD). Due to a long half-life (60-80 hours), a weekly (QW) MK-2206 schedule was pursued to compare intermittent QW and continuous QOD dosing. EXPERIMENTAL DESIGN: Patients with advanced cancers were enrolled in a QW dose-escalation phase I study to investigate the safety and pharmacokinetic-pharmacodynamic profiles of tumor and platelet-rich plasma (PRP). The QOD MTD of MK-2206 was also assessed in patients with ovarian and castration-resistant prostate cancers and patients with advanced cancers undergoing multiparametric functional magnetic resonance imaging (MRI) studies, including dynamic contrast-enhanced MRI, diffusion-weighted imaging, magnetic resonance spectroscopy, and intrinsic susceptibility-weighted MRI. RESULTS: A total of 71 patients were enrolled; 38 patients had 60 mg MK-2206 QOD, whereas 33 received MK-2206 at 90, 135, 150, 200, 250, and 300 mg QW. The QW MK-2206 MTD was established at 200 mg following dose-limiting rash at 250 and 300 mg. QW dosing appeared to be similarly tolerated to QOD, with toxicities including rash, gastrointestinal symptoms, fatigue, and hyperglycemia. Significant AKT pathway blockade was observed with both continuous QOD and intermittent QW dosing of MK-2206 in serially obtained tumor and PRP specimens. The functional imaging studies demonstrated that complex multiparametric MRI protocols may be effectively implemented in a phase I trial. CONCLUSIONS: Treatment with MK-2206 safely results in significant AKT pathway blockade in QOD and QW schedules. The intermittent dose of 200 mg QW is currently used in phase II MK-2206 monotherapy and combination studies (NCT00670488).This study was supported by Merck & Co., Inc. The Drug Development Unit of the
Royal Marsden NHS Foundation Trust and The Institute of Cancer Research is
supported in part by a program grant from Cancer Research U.K. Support was also
provided by the Experimental Cancer Medicine Centre (to The Institute of Cancer
Research), the National Institute for Health Research (NIHR) Biomedical Research
Centre (jointly to the Royal Marsden NHS Foundation Trust and The Institute of
Cancer Research), the NIHR Clinical Research Facility (to the Royal Marsden NHS
Foundation Trust) and the Cancer Research UK and EPSRC Cancer Imaging
Centre. T.A. Yap is the recipient of the 2011 Rebecca and Nathan Milikowsky â PCF
Young Investigator Award and is supported by the NIHR. M.O. Leach is an NIHR
Senior Investigator.This is the accepted manuscript. The final version is available from AACR at http://clincancerres.aacrjournals.org/content/early/2014/09/19/1078-0432.CCR-14-0868
British Society of Gastroenterology guidelines for the diagnosis and management of cholangiocarcinoma
These guidelines for the diagnosis and management of cholangiocarcinoma (CCA) were commissioned by the British Society of Gastroenterology liver section. The guideline writing committee included a multidisciplinary team of experts from various specialties involved in the management of CCA, as well as patient/public representatives from AMMF (the Cholangiocarcinoma Charity) and PSC Support. Quality of evidence is presented using the Appraisal of Guidelines for Research and Evaluation (AGREE II) format. The recommendations arising are to be used as guidance rather than as a strict protocol-based reference, as the management of patients with CCA is often complex and always requires individual patient-centred considerations
Expression of mutant exon 1 huntingtin fragments in human neural stem cells and neurons causes inclusion formation and mitochondrial dysfunction.
Robust cellular models are key in determining pathological mechanisms that lead to neurotoxicity in Huntington's disease (HD) and for high throughput preâclinical screening of potential therapeutic compounds. Such models exist but mostly comprise nonâhuman or nonâneuronal cells that may not recapitulate the correct biochemical milieu involved in pathology. We have developed a new human neuronal cell model of HD, using neural stem cells (ReNcell VM NSCs) stably transduced to express exon 1 huntingtin (HTT) fragments with variable length polyglutamine (polyQ) tracts. Using a system with matched expression levels of exon 1 HTT fragments, we investigated the effect of increasing polyQ repeat length on HTT inclusion formation, location, neuronal survival, and mitochondrial function with a view to creating an in vitro screening platform for therapeutic screening. We found that expression of exon 1 HTT fragments with longer polyQ tracts led to the formation of intraânuclear inclusions in a polyQ lengthâdependent manner during neurogenesis. There was no overt effect on neuronal viability, but defects of mitochondrial function were found in the pathogenic lines. Thus, we have a human neuronal cell model of HD that may recapitulate some of the earliest stages of HD pathogenesis, namely inclusion formation and mitochondrial dysfunction
Set-shifting as a component process of goal-directed problem-solving
In two experiments, we compared secondary task interference on Tower of London performance resulting from three different secondary tasks. The secondary tasks were designed to tap three different executive functions, namely set-shifting, memory monitoring and updating, and response inhibition. Previous work using individual differences methodology suggests that, all other things being equal, the response inhibition or memory tasks should result in the greatest interference. However, this was not found to be the case. Rather, in both experiments the set-shifting task resulted in significantly more interference on Tower of London performance than either of the other secondary tasks. Subsequent analyses suggest that the degree of interference could not be attributed to differences in secondary task difficulty. Results are interpreted in the light of related work which suggests that solving problems with non-transparent goal/subgoal structure requires flexible shifting between subgoals â a process that is held to be impaired by concurrent performance of a set-shifting task
Selection Signatures in Worldwide Sheep Populations
The diversity of populations in domestic species offers great opportunities to study genome response to selection. The recently published Sheep HapMap dataset is a great example of characterization of the world wide genetic diversity in sheep. In this study, we re-analyzed the Sheep HapMap dataset to identify selection signatures in worldwide sheep populations. Compared to previous analyses, we made use of statistical methods that (i) take account of the hierarchical structure of sheep populations, (ii) make use of linkage disequilibrium information and (iii) focus specifically on either recent or older selection signatures. We show that this allows pinpointing several new selection signatures in the sheep genome and distinguishing those related to modern breeding objectives and to earlier post-domestication constraints. The newly identified regions, together with the ones previously identified, reveal the extensive genome response to selection on morphology, color and adaptation to new environments
- âŠ